{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.1","upperLimit":"84.4","value":"77.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"}],"units":"Participants"}],"description":"At the end of the first treatment cycle (Day 29) a bone marrow aspiration/biopsy was performed and evaluated by the central MRD laboratory.\n\nComplete MRD response is defined as no polymerase chain reaction (PCR) amplification of individual rearrangements of immunoglobulin (Ig)- or T-cell receptor (TCR)-genes detected after completion of the first cycle.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"NUMBER","populationDescription":"Primary endpoint full analysis set (Prim EP FAS) included all participants with an Ig TCR PCR MRD assay with the minimum required sensitivity of 1 x 10\\^-4 at central lab established at Baseline.","reportingStatus":"POSTED","timeFrame":"During the first cycle (6 weeks)","title":"Percentage of Participants With a Minimal Residual Disease (MRD) Response Within the First Treatment Cycle","type":"PRIMARY","unitOfMeasure":"percentage of participants"}